Home
About
About Anagenics
Board of Directors
Divisions
Our Divisions
Beauty
Brands
évolis®
Uspa
Investors
Investor Centre
ASX Announcements
2024
2023
2022
2021
2020
2019
Financial Information & Reports
Share Registry Information
Analyst Coverage
Share Information
Anagenics in the media
Newsletter Archive
Corporate Governance
Corporate Governance
Board Charter
Code of Conduct
Policies
Audit Committee Charter
Nomination and Remuneration Committee Charter
Performance Evaluation Process
Corporate Code of Conduct
Environmental, Social and Governance Statement
✕
2014
Home
2014
November 12, 2019
Published by
Tiffany McMillan
on
November 12, 2019
Categories
Release of Shares from Voluntary Escrow
November 12, 2019
Published by
Tiffany McMillan
on
November 12, 2019
Categories
Appendix 4C – quarterly
November 12, 2019
Published by
Tiffany McMillan
on
November 12, 2019
Categories
Significant New Findings Presented at 3rd Midkine Symposium in Kyoto
November 12, 2019
Published by
Tiffany McMillan
on
November 12, 2019
Categories
Key Milestone Completed: Cellmid Lead Antibody Selected for Clinical Trials
November 12, 2019
Published by
Tiffany McMillan
on
November 12, 2019
Categories
Notice of ceasing to be a substantial holder
November 12, 2019
Published by
Tiffany McMillan
on
November 12, 2019
Categories
Change of Director’s Interest Notice – Graeme Kaufman
November 12, 2019
Published by
Tiffany McMillan
on
November 12, 2019
Categories
Manufacturing Partner Appointed by Cellmid
November 12, 2019
Published by
Tiffany McMillan
on
November 12, 2019
Categories
Quest Diagnostic License Update
November 12, 2019
Published by
Tiffany McMillan
on
November 12, 2019
Categories
Landmark Study – FGF5 Critical Regulator of Human Hair Growth
Prev page
1
2
3
4
Next page
